Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
02/2003
02/27/2003CA2458643A1 Nucleic-acid associated proteins
02/27/2003CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
02/27/2003CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis
02/27/2003CA2457482A1 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
02/27/2003CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
02/27/2003CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
02/27/2003CA2456746A1 Method for treating lung cancers
02/27/2003CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms
02/27/2003CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors
02/26/2003WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient
02/26/2003EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
02/26/2003EP1285657A2 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
02/26/2003EP1285087A2 Enzymatic assays for screening anti-cancer agents
02/26/2003EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators
02/26/2003EP1285063A1 Anti-angiogenic polypeptides
02/26/2003EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof
02/26/2003EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
02/26/2003EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators
02/26/2003EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion
02/26/2003EP1284956A1 Il-8 receptor antagonists
02/26/2003EP1284952A1 Substituted chalcones as therapeutic compounds
02/26/2003EP1284771A1 Aerosol container for formulations of salmeterol xinafoate
02/26/2003EP1284740A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono- and disaccharide-based compounds
02/26/2003EP1284738A1 (+) naloxone and epinephrine combination therapy
02/26/2003EP1284727A1 Intracorporeal medicaments for photodynamic treatment of disease
02/26/2003EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
02/26/2003EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
02/26/2003EP1150976B1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
02/26/2003EP1143952B1 Method and composition for treating and preventing tuberculosis
02/26/2003EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors
02/26/2003EP0971901B1 Phthalazinones
02/26/2003EP0934304B1 2-pyrimidineamine derivatives and processes for their preparation
02/26/2003EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
02/26/2003EP0754040B1 Rapamycin derivatives
02/26/2003CN1399678A Human Enzymes of metalloprotease family
02/26/2003CN1399646A Recombinant fusion molecules
02/26/2003CN1399644A Novel human G-Protein coupled receptor
02/26/2003CN1399636A Adenosine receptor antagonists and methods of making and using the same
02/26/2003CN1399633A 嘧啶衍生物 Pyrimidine derivatives
02/26/2003CN1399632A Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as active ingredient
02/26/2003CN1399631A Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
02/26/2003CN1399630A Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments
02/26/2003CN1399540A Aerosol composition comprising formoterol
02/26/2003CN1398960A Cough-relieving wine
02/26/2003CN1398873A Dinucleotide for treating pulmonary tuberulosis
02/26/2003CN1398633A Throat-moistening wild tea
02/26/2003CN1398626A Yinhuang powder injection for intravenous injection and its prepn process
02/26/2003CN1398616A Medicine for treating upper respiratory tract infection and its prepn
02/26/2003CN1398586A New substituted heptoic acid derivative for treating bronchial asthma and chronic obstructive pulmonary tuberculosis
02/26/2003CN1102063C Enqlish yew tea for making throat comfortable
02/26/2003CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient
02/25/2003US6525184 Self-regulated apoptosis of inflammatory cells
02/25/2003US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists
02/25/2003US6525067 Substituted heterocyclic derivatives
02/25/2003US6525059 Substituted pyrazoles as p38 kinase inhibitors
02/25/2003US6525055 Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis.
02/25/2003US6525052 Compounds useful as reversible inhibitors of cysteine proteases
02/25/2003US6525051 For treating cytokine-induced hypotension, inflammatory bowel disease, cerebral ischemia, arthritis, adult respiratory distress syndrome, asthma
02/25/2003US6525040 4,4-dimethyl-thieno-(3,2-e)-isoselenazine; antioxidants and cytoprotecting
02/25/2003US6524557 Aerosol formulations of peptides and proteins
02/25/2003US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant
02/21/2003WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/21/2003CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/20/2003WO2003014745A2 Method for identifying anti-inflammatory drugs
02/20/2003WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
02/20/2003WO2003014316A2 Immunomodulatory compositions, formulations, and methods for use thereof
02/20/2003WO2003014309A2 Interleukin-1 receptors in the treatment of diseases
02/20/2003WO2003014296A2 A group of novel anti-cancer compounds with specific structure
02/20/2003WO2003014294A2 Tacis and br3 polypeptides and uses thereof
02/20/2003WO2003014158A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
02/20/2003WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003WO2003014112A1 Crystal and process for producing the same
02/20/2003WO2003014101A1 Hydroxamic acid derivatives
02/20/2003WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014090A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003WO2003014083A1 Spiro compounds
02/20/2003WO2003014082A1 Cyclopenta ` b ! indole derivatives as spla2 inhibitors
02/20/2003WO2003013655A2 Carbonic anhydrase inhibitors
02/20/2003WO2003013633A1 Inhalation device with a pharmaceutical composition
02/20/2003WO2003013590A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
02/20/2003WO2003013564A2 An herbal composition for the treatment and remedy of bronchial respiratory difficulties
02/20/2003WO2003013547A1 Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
02/20/2003WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits
02/20/2003WO2003013537A2 Irinotecan for treatment of cancer
02/20/2003WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1
02/20/2003WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1
02/20/2003WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5
02/20/2003WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1
02/20/2003WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
02/20/2003WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors
02/20/2003WO2003013513A1 Stable emulsion composition
02/20/2003WO2003013493A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/20/2003WO2003013440A2 Treatment and prevention of heat shock protein-associated diseases and conditions
02/20/2003WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace
02/20/2003WO2003013432A2 Methods of use for novel sulfur containing organic nitrate compounds
02/20/2003WO2003013427A2 A method for preparing fluticasone derivatives
02/20/2003WO2003013424A2 Use of r-nsaid compounds for anti-hiv treatment
02/20/2003WO2002096422A3 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
02/20/2003WO2002086085A3 Human timp-1 antibodies